Maraviroc 150 mg daily plus lopinavir/ritonavir, a nucleoside/nucleotide reverse transcriptase inhibitor-sparing regimen for HIV-infected naive patients: 48-week final results of VEMAN study.
Clin Microbiol Infect
; 21(5): 510.e1-9, 2015 May.
Article
in En
| MEDLINE
| ID: mdl-25656621
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Triazoles
/
HIV Infections
/
Ritonavir
/
Anti-HIV Agents
/
Cyclohexanes
/
Antiretroviral Therapy, Highly Active
/
Lopinavir
Type of study:
Clinical_trials
/
Observational_studies
/
Risk_factors_studies
Limits:
Adult
/
Female
/
Humans
/
Male
Language:
En
Journal:
Clin Microbiol Infect
Journal subject:
DOENCAS TRANSMISSIVEIS
/
MICROBIOLOGIA
Year:
2015
Document type:
Article